Trial reportThe journal of nutrition, health & aging2011
Efficacy of a medical food on cognition in Alzheimer's disease: results from secondary analyses of a randomized, controlled trial.
Trial report in The journal of nutrition, health & aging, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- The effects of omega-3, DHA, EPA, Souvenaid® in Alzheimer's disease: A systematic review and meta-analysis.Neuropsychopharmacology reports · 2024Pooled it
- Souvenaid for Alzheimer's disease.The Cochrane database of systematic reviews · 2020Pooled it
- Omega-3 Fatty Acids and Neurodegenerative Diseases: New Evidence in Clinical Trials.International journal of molecular sciences · 2019Pooled it
- Effectiveness of interventions to directly support food and drink intake in people with dementia: systematic review and meta-analysis.BMC geriatrics · 2016Pooled it
- 24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial.The Lancet. Neurology · 2017Trial
- Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer's disease.Alzheimer's research & therapy · 2015Trial
- Review
- Mediterranean diet, micronutrients and macronutrients, and MRI measures of cortical thickness.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2017Article
- Anti-dementia medications: current prescriptions in clinical practice and new agents in progress.Therapeutic advances in drug safety · 2015Review
- Nutrition and prevention of Alzheimer's dementia.Frontiers in aging neuroscience · 2014Review
- Frailty and cognition: linking two common syndromes in older persons.The journal of nutrition, health & aging · 2013Article
- Nutrition and neurodegeneration: epidemiological evidence and challenges for future research.British journal of clinical pharmacology · 2013Review
- Effects of specific multi-nutrient enriched diets on cerebral metabolism, cognition and neuropathology in AβPPswe-PS1dE9 mice.PloS one · 2013Article
- The S-Connect study: results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimer's disease.Alzheimer's research & therapy · 2013Article
- Use of medical foods and nutritional approaches in the treatment of Alzheimer's disease.Clinical practice (London, England) · 2012Article
- The multidimentionality of frailty: many faces of one single dice.The journal of nutrition, health & aging · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the extent that baseline cognitive impairment and intake adherence affected the 13-item Alzheimer's Disease Assessment Scale - cognitive subscale (ADAS-cog) intervention response of a medical food in Alzheimer's Disease (AD) patients. DESIGN/SETTING/PARTICIPANTS /INTERVENTION/MEASUREMENTS: This analysis was performed on data from a proof-of-concept study, consisting of a 12-week, double-blind, randomized, controlled, multicenter trial, followed by a similarly designed 12-week extension study. Patients with mild AD (Mini-Mental State Examination [MMSE] score of 20-26) were randomized to receive active or control product as a 125 ml daily drink. One of the co-primary outcome measures was the 13-item ADAS-cog. In this analysis, the study population was divided into two subgroups: patients with 'low' baseline ADAS-cog scores (<25.0) and patients with 'high' baseline ADAS-cog scores (≥25.0). Repeated Measures Models (RMM) were used to determine the relationship between ADAS-cog score and intervention.
resultsA significant treatment effect (F[1,319]=4.0, p=0.046) was shown in patients with 'high' baseline ADAS-cog, but not in patients with 'low' baseline ADAS-cog (F[1,250]=1.25, p=0.265). Overall, intake adherence was significantly correlated with ADAS-cog improvement in the active product group (correlation coefficient=-0.260; p=0.019), but not the control group.
conclusionThese data indicate that baseline ADAS-cog significantly influenced the effect of Souvenaid intervention on ADAS-cog outcome. A higher intake of active study product was also associated with greater cognitive benefit. These findings highlight the potential benefits of Souvenaid in AD patients and warrant confirmation in larger, controlled studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.